Nicox S.A. (ALCOX) is a Biotechnology company in the Healthcare sector, listed on Euronext Paris. This page provides the complete earnings calendar, dividend schedule, and financial data for Nicox S.A. in 2026. The next earnings report is expected on September 2, 2026.
Next earnings date
02 Sep 2026
In 13 days
EPS estimate
—
Revenue estimate
—
Past earnings
Latest earnings analysis
Consensus estimates were not provided, and Nicox S.A. posted EPS of USD 0.094 and revenue of USD 20.29 million. No prior report is available to indicate whether its EPS and revenue were ahead of or below expectations.
No dividend history available.
Nicox S.A. is an ophthalmology firm operating both within France and internationally, dedicated to developing treatments that preserve sight and enhance eye health. Its most advanced investigational therapy, NCX 470, is a unique nitric oxide-donating bimatoprost eye drop currently undergoing Phase 3 clinical trials, designed to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also progressing NCX 4251, a proprietary ophthalmic suspension containing fluticasone propionate nanocrystals, which is in Phase 2b development for the treatment of dry eye disease. Additionally, Nicox has NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, in its preclinical assessment stage. Beyond its pipeline, Nicox markets VYZULTA, a latanoprostene bunod ophthalmic solution prescribed for open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution used to alleviate ocular itching linked to allergic conjunctivitis. Established in 1996, Nicox S.A. maintains its headquarters in Valbonne, France.
Nicox S.A. (ALCOX) is scheduled to report earnings on September 2, 2026.
Nicox S.A. (ALCOX) last reported earnings on April 30, 2026.
Nicox S.A. (ALCOX) is listed on Euronext Paris.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.